These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 9091463)
21. The promise FDG in diagnosis and surveillance of head and neck cancer. Mancuso AA; Drane WE; Mukherji SK Cancer; 1994 Aug; 74(4):1193-5. PubMed ID: 8055436 [No Abstract] [Full Text] [Related]
22. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. Ichiya Y; Kuwabara Y; Otsuka M; Tahara T; Yoshikai T; Fukumura T; Jingu K; Masuda K J Nucl Med; 1991 Sep; 32(9):1655-60. PubMed ID: 1880564 [TBL] [Abstract][Full Text] [Related]
23. PET and [18F]-FDG in oncology: a clinical update. Conti PS; Lilien DL; Hawley K; Keppler J; Grafton ST; Bading JR Nucl Med Biol; 1996 Aug; 23(6):717-35. PubMed ID: 8940714 [TBL] [Abstract][Full Text] [Related]
24. PET scans of abdominal malignancy. Blahd WH; Brown CV; Khonsary SA; Farahi JB; Quinones N; Ribe JY; Coyle JJ; Glass EC; Mandelkern MA World J Surg; 1996 Feb; 20(2):245-7. PubMed ID: 8661826 [TBL] [Abstract][Full Text] [Related]
25. Cancer or inflammation? A Holy Grail for nuclear medicine. Larson SM J Nucl Med; 1994 Oct; 35(10):1653-5. PubMed ID: 7931666 [No Abstract] [Full Text] [Related]
27. [Diagnosis of early cancer with positron emission tomography]. Kubota K Nihon Rinsho; 1996 May; 54(5):1263-7. PubMed ID: 8965348 [TBL] [Abstract][Full Text] [Related]
29. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. Makler PT J Nucl Med; 1997 Jul; 38(7):1173-4. PubMed ID: 9225819 [No Abstract] [Full Text] [Related]
30. PET with fluorine-18 deoxyglucose for pancreatic disease. Klever P; Bares R; Fass J; Büll U; Schumpelick V Lancet; 1992 Nov; 340(8828):1158-9. PubMed ID: 1359226 [No Abstract] [Full Text] [Related]
32. Is there a role for FDG PET imaging in the management of patients with sarcoidosis? Alavi A; Buchpiguel CA; Loessner A J Nucl Med; 1994 Oct; 35(10):1650-2. PubMed ID: 7931665 [No Abstract] [Full Text] [Related]
33. FDG-PET in oncology: there's more to it than looking at pictures. Fischman AJ; Alpert NM J Nucl Med; 1993 Jan; 34(1):6-11. PubMed ID: 8418272 [No Abstract] [Full Text] [Related]
34. Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future. Minn H; Paul R Eur J Nucl Med; 1992; 19(11):921-4. PubMed ID: 1425778 [No Abstract] [Full Text] [Related]
35. [Positron emitters for the study of tumor metabolism]. Strauss LG Radiologe; 1989 Jul; 29(7):318-21. PubMed ID: 2667030 [TBL] [Abstract][Full Text] [Related]
37. What are the sources of error in measuring and calculating cerebral metabolic rates with fluorine-18-fluorodeoxyglucose and PET? Alavi A; Smith R; Duncan D J Nucl Med; 1994 Sep; 35(9):1466-70. PubMed ID: 8071693 [No Abstract] [Full Text] [Related]
38. Positron emission tomography (PET) in the evaluation of patients with cancer. Godwin HA; Zuger JH Trans Am Clin Climatol Assoc; 1999; 110():181-94. PubMed ID: 10344016 [No Abstract] [Full Text] [Related]
39. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. Schmidt KC; Lucignani G; Sokoloff L J Nucl Med; 1996 Feb; 37(2):394-9. PubMed ID: 8667082 [No Abstract] [Full Text] [Related]
40. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Sundaresan SR; Patterson GA; Cooper JD AJR Am J Roentgenol; 1997 Feb; 168(2):417-24. PubMed ID: 9016218 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]